Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Circular RNA circAGO2 drives cancer progression through facilitating HuR-repressed functions of AGO2-miRNA complexes.

Chen Y, Yang F, Fang E, Xiao W, Mei H, Li H, Li D, Song H, Wang J, Hong M, Wang X, Huang K, Zheng L, Tong Q.

Cell Death Differ. 2018 Oct 19. doi: 10.1038/s41418-018-0220-6. [Epub ahead of print]

PMID:
30341421
2.

Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.

Bowler E, Porazinski S, Uzor S, Thibault P, Durand M, Lapointe E, Rouschop KMA, Hancock J, Wilson I, Ladomery M.

BMC Cancer. 2018 Apr 2;18(1):355. doi: 10.1186/s12885-018-4227-7.

3.

Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.

Liu H, Song X, Hou J, Zhao Z, Chang J.

DNA Cell Biol. 2018 Mar;37(3):210-219. doi: 10.1089/dna.2017.3940. Epub 2018 Jan 12.

PMID:
29327946
4.

Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer.

Mitsunari K, Miyata Y, Asai A, Matsuo T, Shida Y, Hakariya T, Sakai H.

Transl Res. 2016 Sep;175:116-28. doi: 10.1016/j.trsl.2016.04.002. Epub 2016 Apr 29.

5.

Long non-coding RNAs harboring miRNA seed regions are enriched in prostate cancer exosomes.

Ahadi A, Brennan S, Kennedy PJ, Hutvagner G, Tran N.

Sci Rep. 2016 Apr 22;6:24922. doi: 10.1038/srep24922.

6.

Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.

Melling N, Taskin B, Hube-Magg C, Kluth M, Minner S, Koop C, Grob T, Graefen M, Heinzer H, Tsourlakis MC, Izbicki J, Wittmer C, Huland H, Simon R, Wilczak W, Sauter G, Steurer S, Schlomm T, Krech T.

Prostate. 2016 Feb 15;76(3):259-72. doi: 10.1002/pros.23120. Epub 2015 Nov 2.

PMID:
26764246
7.

Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis.

Kim T, Jeon YJ, Cui R, Lee JH, Peng Y, Kim SH, Tili E, Alder H, Croce CM.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: dju505. doi: 10.1093/jnci/dju505. Print 2015 Apr.

8.

Control of pro-angiogenic cytokine mRNA half-life in cancer: the role of AU-rich elements and associated proteins.

Griseri P, Pagès G.

J Interferon Cytokine Res. 2014 Apr;34(4):242-54. doi: 10.1089/jir.2013.0140. Review.

PMID:
24697202
9.

The prolyl isomerase pin1 regulates mRNA levels of genes with short half-lives by targeting specific RNA binding proteins.

Krishnan N, Titus MA, Thapar R.

PLoS One. 2014 Jan 9;9(1):e85427. doi: 10.1371/journal.pone.0085427. eCollection 2014.

10.

Apoptotic markers in a prostate cancer cell line: effect of ellagic acid.

Vanella L, Di Giacomo C, Acquaviva R, Barbagallo I, Cardile V, Kim DH, Abraham NG, Sorrenti V.

Oncol Rep. 2013 Dec;30(6):2804-10. doi: 10.3892/or.2013.2757. Epub 2013 Sep 30.

PMID:
24085108
11.
12.

The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells.

Epis MR, Barker A, Giles KM, Beveridge DJ, Leedman PJ.

J Biol Chem. 2011 Dec 2;286(48):41442-54. doi: 10.1074/jbc.M111.301481. Epub 2011 Oct 4.

13.

Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions.

Chae KS, Kang MJ, Lee JH, Ryu BK, Lee MG, Her NG, Ha TK, Han J, Kim YK, Chi SG.

Oncogene. 2011 Mar 10;30(10):1213-28. doi: 10.1038/onc.2010.498. Epub 2010 Nov 8.

PMID:
21057546
14.

MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.

Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M.

Prostate. 2010 Oct 1;70(14):1501-12. doi: 10.1002/pros.21185.

PMID:
20687223
15.

The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis.

Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM.

Cancer Res. 2009 Jun 15;69(12):5168-76. doi: 10.1158/0008-5472.CAN-08-4238. Epub 2009 Jun 2.

16.

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.

Kandasamy K, Kraft AS.

Mol Cancer Ther. 2008 May;7(5):1091-100. doi: 10.1158/1535-7163.MCT-07-2368.

17.

Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies.

Barbisan F, Mazzucchelli R, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montorsi F, Montironi R.

Eur Urol. 2009 Jul;56(1):105-12. doi: 10.1016/j.eururo.2008.04.043. Epub 2008 Apr 30.

PMID:
18468781
18.

Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.

Niesporek S, Kristiansen G, Thoma A, Weichert W, Noske A, Buckendahl AC, Jung K, Stephan C, Dietel M, Denkert C.

Int J Oncol. 2008 Feb;32(2):341-7.

PMID:
18202756
19.
20.

Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.

Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R.

Anticancer Drugs. 2006 Apr;17(4):429-38.

PMID:
16550001

Supplemental Content

Loading ...
Support Center